Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
AACR, Abemaciclig, accomplished, acknowledgement, advocacy, analytical, Argentina, Belize, bioavailability, Bipartisan, black, blinded, Bolivia, box, Brazil, breast, British, carcinogenicity, CDK, Chile, China, Chinese, chosen, CMS, Colombia, copy, Costa, CRADA, Cuba, cyber, DC, dear, disgorgement, Dominican, driver, dual, Ecuador, El, embarking, enasidenib, ester, forthcoming, France, French, genetic, germline, grace, Guatemala, Guiana, Haiti, HanX, HCW, hearing, hematopoietic, highlighted, hrs, Ibrance, IEC, incorrect, inhibitor, inhibitory, internationally, invoice, ivosidenib, JMML, junior, Juvenile, Laidlaw, lend, leukemic, Mexico, molecularly, multifaceted, NCI, Nicaragua, NIH, nonoccurrence, novelty, OS, overcome, Palbociclib, Panama, Paraguay, parity, PCAOB, penny, Peru, Pfizer, Pint, Pivotal, plausible, potency, predefined, Preliminarily, pro, prominent, provisional, purity, qualitative, quantitative, rank, ranking, RASopathiesNet, RASopathy, rata, RBC, ready, Reauthorization, recapitalization, reclassification, regime, reorganization, Republic, resubmit, Ribociclib, Rica, salt, Salvador, SAP, screening, Sock, South, Src, statutorily, strength, stricter, subfamily, Suriname, technique, trail, transduction, transfusion, undercut, underwritten, unexpired, unissued, unrepatriated, unreserved, Uruguay, USA, Venezuela, VHR, Wainwright, Washington, xenograft
Filing tables
Filing exhibits
Related press release
Associated TRAW transcripts
TRAW similar filings
Filing view
External links
QuickLinks -- Click here to rapidly navigate through this document
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Onconova Therapeutics, Inc. (the "Company") for the year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Ramesh Kumar, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that, based on my knowledge:
- (1)
- The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2)
- The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| /s/ RAMESH KUMAR, PH.D. Ramesh Kumar, Ph.D. President and Chief Executive Officer (Principal Executive Officer and Principal Operating Officer) |
Dated: March 16, 2018
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002